408 related articles for article (PubMed ID: 26998881)
1. Toll-like receptors in hepatocellular carcinoma: potential novel targets for pharmacological intervention.
Zou H; Wang WK; Liu YL; Braddock M; Zheng MH; Huang DS
Expert Opin Ther Targets; 2016 Sep; 20(9):1127-35. PubMed ID: 26998881
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptors as targets for immune disorders.
Keogh B; Parker AE
Trends Pharmacol Sci; 2011 Jul; 32(7):435-42. PubMed ID: 21529972
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.
Li TT; Ogino S; Qian ZR
World J Gastroenterol; 2014 Dec; 20(47):17699-708. PubMed ID: 25548469
[TBL] [Abstract][Full Text] [Related]
4. RAGE and TLRs: relatives, friends or neighbours?
Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
[TBL] [Abstract][Full Text] [Related]
5. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
6. The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseases.
Lin Q; Li M; Fang D; Fang J; Su SB
Int Immunopharmacol; 2011 Oct; 11(10):1422-32. PubMed ID: 21600309
[TBL] [Abstract][Full Text] [Related]
7. [Innate immunity: structure and function of TLRs].
Delneste Y; Beauvillain C; Jeannin P
Med Sci (Paris); 2007 Jan; 23(1):67-73. PubMed ID: 17212934
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor regulation of effector T lymphocyte function.
Reynolds JM; Dong C
Trends Immunol; 2013 Oct; 34(10):511-9. PubMed ID: 23886621
[TBL] [Abstract][Full Text] [Related]
9. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells.
Tartey S; Takeuchi O
Int Rev Immunol; 2017 Mar; 36(2):57-73. PubMed ID: 28060562
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptors and innate immunity.
Kumar H; Kawai T; Akira S
Biochem Biophys Res Commun; 2009 Oct; 388(4):621-5. PubMed ID: 19686699
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
Cui J; Chen Y; Wang HY; Wang RF
Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
[TBL] [Abstract][Full Text] [Related]
12. STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma.
Li W; Xiao J; Zhou X; Xu M; Hu C; Xu X; Lu Y; Liu C; Xue S; Nie L; Zhang H; Li Z; Zhang Y; Ji F; Hui L; Tao W; Wei B; Wang H
J Clin Invest; 2015 Nov; 125(11):4239-54. PubMed ID: 26457732
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptors in inflammation of the central nervous system.
Kong Y; Le Y
Int Immunopharmacol; 2011 Oct; 11(10):1407-14. PubMed ID: 21600311
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy.
Yang Y; Feng R; Wang YZ; Sun HW; Zou QM; Li HB
Immunol Lett; 2020 Jul; 223():1-9. PubMed ID: 32311408
[TBL] [Abstract][Full Text] [Related]
15. Role of toll-like receptors gene polymorphism in hepatocellular carcinoma.
Lin W; Chen J; Zhu B; Xu X; Dong Z
J Recept Signal Transduct Res; 2014 Oct; 34(5):345-7. PubMed ID: 24641696
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic targets and predictive markers for hepatocellular carcinoma.
Chan SL; Chan AW; Yeo W
Expert Opin Ther Targets; 2015 Jul; 19(7):973-83. PubMed ID: 25910512
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor-mediated innate immunity against herpesviridae infection: a current perspective on viral infection signaling pathways.
Zheng W; Xu Q; Zhang Y; E X; Gao W; Zhang M; Zhai W; Rajkumar RS; Liu Z
Virol J; 2020 Dec; 17(1):192. PubMed ID: 33298111
[TBL] [Abstract][Full Text] [Related]
18. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense.
Basith S; Manavalan B; Yoo TH; Kim SG; Choi S
Arch Pharm Res; 2012 Aug; 35(8):1297-316. PubMed ID: 22941474
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors and innate immunity.
Uematsu S; Akira S
J Mol Med (Berl); 2006 Sep; 84(9):712-25. PubMed ID: 16924467
[TBL] [Abstract][Full Text] [Related]
20. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs.
Pez F; Lopez A; Kim M; Wands JR; Caron de Fromentel C; Merle P
J Hepatol; 2013 Nov; 59(5):1107-17. PubMed ID: 23835194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
